St. Jude Venture catheter
This article was originally published in The Gray Sheet
Executive Summary
Firm gains 510(k) clearance for its Venture wire control catheter for use with a rapid exchange delivery platform. The rapid exchange delivery method accommodates shorter guidewires, which may result in quicker, easier coronary procedures, the firm says. The Venture catheter, first approved in 2005 for use with an over-the-wire system, features a deflectable tip, allowing interventional cardiologists to treat difficult-to-reach areas in the heart. St. Jude obtained Venture in its 2005 acquisition of Velocimed (1"The Gray Sheet" Feb. 21, 2005, p. 9)...
You may also be interested in...
St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal
St. Jude Medical will accelerate its patent foramen ovale (PFO) R&D program for stroke treatment by acquiring Velocimed for more than $82.5 mil. under a definitive agreement, the firms said Feb. 15
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.